SCHEMBL2403448

SCHEMBL2403448

O=C(Nc1ccccc1Cl)Oc1ccc2ncccc2c1

nearest known ligand 0.72

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 1/20 0.72
ALDH1A1 P00352 1/20 0.63
MEN1 O00255 6/20 0.55
KMT2A Q03164 6/20 0.55
CASP3 P42574 2/20 0.50
SENP7 Q9BQF6 2/20 0.50
SENP8 Q96LD8 1/20 0.50
NPC1 O15118 5/20 0.49
RAB9A P51151 4/20 0.49
POLB P06746 2/20 0.48
DOT1L Q8TEK3 1/20 0.48
HTT P42858 3/20 0.48
SMN1; SMN2 Q16637 1/20 0.48
HDAC1 Q13547 1/20 0.46
HDAC2 Q92769 1/20 0.46
MAPT P10636 1/20 0.46
HDAC3 O15379 1/20 0.45
ACHE P22303 1/20 0.44
PABPC1 P11940 1/20 0.44
ALOX15 P16050 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28663512 0.82 ALDH1A1 (0.69) ALDH1A1MEN1KMT2ANPC1RAB9A
SCHEMBL19924516 0.77 ALDH1A1 (0.69) KDM4EALDH1A1MEN1KMT2ANPC1
SCHEMBL6985088 0.76 ALDH1A1 (0.67) KDM4EALDH1A1MEN1KMT2ANPC1
SCHEMBL10876790 0.75 HSP90AA1 (0.68) KDM4EMEN1KMT2ACASP3SENP7
SCHEMBL2403473 0.75 ALDH1A1 (0.62) ALDH1A1MEN1KMT2ACASP3SENP7
SCHEMBL1568786 0.74 PABPC1 (0.65) KDM4EALDH1A1MEN1KMT2ACASP3
SCHEMBL5267380 0.74 ALDH1A1 (0.68) KDM4EALDH1A1MEN1KMT2ANPC1
SCHEMBL19924517 0.74 ALDH1A1 (0.64) ALDH1A1MEN1KMT2ANPC1RAB9A
SCHEMBL11292311 0.74 KDM4E (0.70) KDM4EALDH1A1MEN1KMT2ACASP3
SCHEMBL3984621 0.74 MEN1 (0.82) KDM4EALDH1A1MEN1KMT2ANPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7655801-B2 Substituted carbamic acid quinolin-6-yl esters useful as acetylcholinesterase inhibitors COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) 2010-02-02 US claimed
EP-1831172-B1 SUBSTITUTED CARBAMIC ACID QUINOLIN-6-YL ESTERS USEFUL AS ACETYLCHOLINESTERASE INHIBITORS COUNCIL SCIENT IND RES (IN) 2009-02-18 EP claimed
EP-1831172-A1 SUBSTITUTED CARBAMIC ACID QUINOLIN-6-YL ESTERS USEFUL AS ACETYLCHOLINESTERASE INHIBITORS Council of Scientific and Industrial Research (IN) 2007-09-12 EP claimed
WO-2006070394-A1 SUBSTITUTED CARBAMIC ACID QUINOLIN-6-YL ESTERS USEFUL AS ACETYLCHOLINESTERASE INHIBITORS COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) 2006-07-06 WO claimed
US-20060142335-A1 Substituted carbamic acid quinolin-6-yl esters useful as acetylcholinesterase inhibitors COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH 2006-06-29 US claimed
US-20220265685-A1 METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION THE JOHNS HOPKINS UNIVERSITY 2022-08-25 US disclosed
US-11160785-B2 Methods and compositions for improving cognitive function AGENEBIO INC. (US) 2021-11-02 US disclosed
US-20180015109-A1 METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION THE JOHNS HOPKINS UNIVERSITY 2018-01-18 US disclosed
US-20160271108-A1 METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION AGENEBIO, INC. 2016-09-22 US disclosed
EP-2533645-B1 METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION UNIV JOHNS HOPKINS (US) 2016-07-27 EP disclosed
EP-2968220-A1 METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION Agenebio, Inc. (US) 2016-01-20 EP disclosed
WO-2014144801-A1 METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION AGENEBIO INC. (US) 2014-09-18 WO disclosed
US-20110212928-A1 METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION THE JOHNS HOPKINS UNIVERSITY (US) 2011-09-01 US disclosed
US-7655801-B2 Substituted carbamic acid quinolin-6-yl esters useful as acetylcholinesterase inhibitors COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) 2010-02-02 US disclosed
EP-1831172-B1 SUBSTITUTED CARBAMIC ACID QUINOLIN-6-YL ESTERS USEFUL AS ACETYLCHOLINESTERASE INHIBITORS COUNCIL SCIENT IND RES (IN) 2009-02-18 EP disclosed
EP-1831172-A1 SUBSTITUTED CARBAMIC ACID QUINOLIN-6-YL ESTERS USEFUL AS ACETYLCHOLINESTERASE INHIBITORS Council of Scientific and Industrial Research (IN) 2007-09-12 EP disclosed
WO-2006070394-A1 SUBSTITUTED CARBAMIC ACID QUINOLIN-6-YL ESTERS USEFUL AS ACETYLCHOLINESTERASE INHIBITORS COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) 2006-07-06 WO disclosed
US-20060142335-A1 Substituted carbamic acid quinolin-6-yl esters useful as acetylcholinesterase inhibitors COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH 2006-06-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160271108-A1 METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION BACE2, BACE1, GRIN2A KDM4E 3701/4885ALDH1A1 1226/4885MEN1 4306/4885
US-11160785-B2 Methods and compositions for improving cognitive function BACE2, BACE1, GRIN2A KDM4E 3701/4885ALDH1A1 1226/4885MEN1 4306/4885
US-20180015109-A1 METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION BACE1, BACE2, ACHE KDM4E 3495/4885ALDH1A1 2614/4885MEN1 4285/4885
US-20060142335-A1 Substituted carbamic acid quinolin-6-yl esters useful as acetylcholinesterase inhibitors ACHE, BCHE, NAAA KDM4E 589/4885ALDH1A1 885/4885MEN1 2275/4885
US-20220265685-A1 METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION BACE1, BACE2, ACHE KDM4E 3495/4885ALDH1A1 2614/4885MEN1 4285/4885
US-20110212928-A1 METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION BACE1, BACE2, ACHE KDM4E 3495/4885ALDH1A1 2614/4885MEN1 4285/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.